Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Buy
52
INFU Quote, Financials, Valuation and Earnings
Last price:
$8.92
Seasonality move
:
-0.07%
Day range:
$8.75 - $9.14
52-week range:
$4.61 - $11.04
Dividend yield:
0%
P/E ratio:
34.26x
P/S ratio:
1.35x
P/B ratio:
3.28x
Volume:
131.6K
Avg. volume:
120K
1-year change:
9.8%
Market cap:
$182.2M
Revenue:
$134.9M
EPS (TTM):
$0.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
INFU
InfuSystem Holdings, Inc.
|
$36.8M | $0.05 | 8.36% | 39.86% | $14.20 |
|
CATX
Perspective Therapeutics, Inc.
|
$206.8K | -$0.32 | -9.65% | -37.91% | $12.3077 |
|
RMD
ResMed, Inc.
|
$1.3B | $2.50 | 8.96% | 16.17% | $291.80 |
|
VNRX
VolitionRX Ltd.
|
$715.6K | -$0.05 | 272.5% | -33.67% | $2.20 |
|
VTAK
Catheter Precision, Inc.
|
$310K | -$0.20 | 118.75% | -11.57% | -- |
|
XTNT
Xtant Medical Holdings, Inc.
|
$32.7M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
INFU
InfuSystem Holdings, Inc.
|
$8.96 | $14.20 | $182.2M | 34.26x | $0.00 | 0% | 1.35x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8800 | $12.3077 | $214.1M | -- | $0.00 | 0% | 195.28x |
|
RMD
ResMed, Inc.
|
$244.76 | $291.80 | $35.7B | 25.05x | $0.60 | 0.92% | 6.85x |
|
VNRX
VolitionRX Ltd.
|
$0.25 | $2.20 | $30.7M | -- | $0.00 | 0% | 17.13x |
|
VTAK
Catheter Precision, Inc.
|
$1.68 | -- | $2.1M | 0.40x | $0.00 | 0% | 7.90x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.78 | $1.50 | $108.6M | 76.08x | $0.00 | 0% | 0.85x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 3.833 | 11.73% | 1.35x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.691 | 1.3% | 8.47x |
|
RMD
ResMed, Inc.
|
12.15% | 0.692 | 2.12% | 1.89x |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.566 | 15.4% | 0.04x |
|
VTAK
Catheter Precision, Inc.
|
68.63% | -0.348 | 537.37% | 0.41x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 2.955 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
RMD
ResMed, Inc.
|
$808.9M | $462.3M | 22.25% | 25.6% | 34.62% | $411.5M |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
VTAK
Catheter Precision, Inc.
|
-$320K | -$3M | -79.27% | -192.05% | -1336.73% | -$2.2M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
InfuSystem Holdings, Inc. vs. Competitors
-
Which has Higher Returns INFU or CATX?
Perspective Therapeutics, Inc. has a net margin of 6.19% compared to InfuSystem Holdings, Inc.'s net margin of -12425.36%. InfuSystem Holdings, Inc.'s return on equity of 9.93% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About INFU or CATX?
InfuSystem Holdings, Inc. has a consensus price target of $14.20, signalling upside risk potential of 58.48%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 327.35%. Given that Perspective Therapeutics, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INFUInfuSystem Holdings, Inc.5 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is INFU or CATX More Risky?
InfuSystem Holdings, Inc. has a beta of 1.708, which suggesting that the stock is 70.763% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.
-
Which is a Better Dividend Stock INFU or CATX?
InfuSystem Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InfuSystem Holdings, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INFU or CATX?
InfuSystem Holdings, Inc. quarterly revenues are $36.5M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. InfuSystem Holdings, Inc.'s net income of $2.3M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, InfuSystem Holdings, Inc.'s price-to-earnings ratio is 34.26x while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystem Holdings, Inc. is 1.35x versus 195.28x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INFUInfuSystem Holdings, Inc.1.35x 34.26x $36.5M $2.3M CATXPerspective Therapeutics, Inc.195.28x -- $209K -$26M
-
Which has Higher Returns INFU or RMD?
ResMed, Inc. has a net margin of 6.19% compared to InfuSystem Holdings, Inc.'s net margin of 26.1%. InfuSystem Holdings, Inc.'s return on equity of 9.93% beat ResMed, Inc.'s return on equity of 25.6%.
Company Gross Margin Earnings Per Share Invested Capital INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M RMDResMed, Inc.60.56% $2.37 $7B -
What do Analysts Say About INFU or RMD?
InfuSystem Holdings, Inc. has a consensus price target of $14.20, signalling upside risk potential of 58.48%. On the other hand ResMed, Inc. has an analysts' consensus of $291.80 which suggests that it could grow by 19.22%. Given that InfuSystem Holdings, Inc. has higher upside potential than ResMed, Inc., analysts believe InfuSystem Holdings, Inc. is more attractive than ResMed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INFUInfuSystem Holdings, Inc.5 0 0 RMDResMed, Inc.8 7 1 -
Is INFU or RMD More Risky?
InfuSystem Holdings, Inc. has a beta of 1.708, which suggesting that the stock is 70.763% more volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.363%.
-
Which is a Better Dividend Stock INFU or RMD?
InfuSystem Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed, Inc. offers a yield of 0.92% to investors and pays a quarterly dividend of $0.60 per share. InfuSystem Holdings, Inc. pays -- of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios INFU or RMD?
InfuSystem Holdings, Inc. quarterly revenues are $36.5M, which are smaller than ResMed, Inc. quarterly revenues of $1.3B. InfuSystem Holdings, Inc.'s net income of $2.3M is lower than ResMed, Inc.'s net income of $348.5M. Notably, InfuSystem Holdings, Inc.'s price-to-earnings ratio is 34.26x while ResMed, Inc.'s PE ratio is 25.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystem Holdings, Inc. is 1.35x versus 6.85x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INFUInfuSystem Holdings, Inc.1.35x 34.26x $36.5M $2.3M RMDResMed, Inc.6.85x 25.05x $1.3B $348.5M
-
Which has Higher Returns INFU or VNRX?
VolitionRX Ltd. has a net margin of 6.19% compared to InfuSystem Holdings, Inc.'s net margin of -862.39%. InfuSystem Holdings, Inc.'s return on equity of 9.93% beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About INFU or VNRX?
InfuSystem Holdings, Inc. has a consensus price target of $14.20, signalling upside risk potential of 58.48%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 780%. Given that VolitionRX Ltd. has higher upside potential than InfuSystem Holdings, Inc., analysts believe VolitionRX Ltd. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INFUInfuSystem Holdings, Inc.5 0 0 VNRXVolitionRX Ltd.4 2 0 -
Is INFU or VNRX More Risky?
InfuSystem Holdings, Inc. has a beta of 1.708, which suggesting that the stock is 70.763% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.
-
Which is a Better Dividend Stock INFU or VNRX?
InfuSystem Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InfuSystem Holdings, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INFU or VNRX?
InfuSystem Holdings, Inc. quarterly revenues are $36.5M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. InfuSystem Holdings, Inc.'s net income of $2.3M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, InfuSystem Holdings, Inc.'s price-to-earnings ratio is 34.26x while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystem Holdings, Inc. is 1.35x versus 17.13x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INFUInfuSystem Holdings, Inc.1.35x 34.26x $36.5M $2.3M VNRXVolitionRX Ltd.17.13x -- $627.3K -$5.4M
-
Which has Higher Returns INFU or VTAK?
Catheter Precision, Inc. has a net margin of 6.19% compared to InfuSystem Holdings, Inc.'s net margin of -1037.17%. InfuSystem Holdings, Inc.'s return on equity of 9.93% beat Catheter Precision, Inc.'s return on equity of -192.05%.
Company Gross Margin Earnings Per Share Invested Capital INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M -
What do Analysts Say About INFU or VTAK?
InfuSystem Holdings, Inc. has a consensus price target of $14.20, signalling upside risk potential of 58.48%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 2161.97%. Given that Catheter Precision, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Catheter Precision, Inc. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INFUInfuSystem Holdings, Inc.5 0 0 VTAKCatheter Precision, Inc.0 0 0 -
Is INFU or VTAK More Risky?
InfuSystem Holdings, Inc. has a beta of 1.708, which suggesting that the stock is 70.763% more volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.301, suggesting its less volatile than the S&P 500 by 230.084%.
-
Which is a Better Dividend Stock INFU or VTAK?
InfuSystem Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InfuSystem Holdings, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INFU or VTAK?
InfuSystem Holdings, Inc. quarterly revenues are $36.5M, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. InfuSystem Holdings, Inc.'s net income of $2.3M is higher than Catheter Precision, Inc.'s net income of -$2.3M. Notably, InfuSystem Holdings, Inc.'s price-to-earnings ratio is 34.26x while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystem Holdings, Inc. is 1.35x versus 7.90x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INFUInfuSystem Holdings, Inc.1.35x 34.26x $36.5M $2.3M VTAKCatheter Precision, Inc.7.90x 0.40x $226K -$2.3M
-
Which has Higher Returns INFU or XTNT?
Xtant Medical Holdings, Inc. has a net margin of 6.19% compared to InfuSystem Holdings, Inc.'s net margin of 3.93%. InfuSystem Holdings, Inc.'s return on equity of 9.93% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About INFU or XTNT?
InfuSystem Holdings, Inc. has a consensus price target of $14.20, signalling upside risk potential of 58.48%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 93.3%. Given that Xtant Medical Holdings, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INFUInfuSystem Holdings, Inc.5 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is INFU or XTNT More Risky?
InfuSystem Holdings, Inc. has a beta of 1.708, which suggesting that the stock is 70.763% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.
-
Which is a Better Dividend Stock INFU or XTNT?
InfuSystem Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InfuSystem Holdings, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INFU or XTNT?
InfuSystem Holdings, Inc. quarterly revenues are $36.5M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. InfuSystem Holdings, Inc.'s net income of $2.3M is higher than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, InfuSystem Holdings, Inc.'s price-to-earnings ratio is 34.26x while Xtant Medical Holdings, Inc.'s PE ratio is 76.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystem Holdings, Inc. is 1.35x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INFUInfuSystem Holdings, Inc.1.35x 34.26x $36.5M $2.3M XTNTXtant Medical Holdings, Inc.0.85x 76.08x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 29
Galecto, Inc. [GLTO] is down 12.13% over the past day.
Sell
20
SMX alert for Dec 29
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Sell
11
CDNAF alert for Dec 29
Canadian Tire Corp. Ltd. [CDNAF] is up 11.94% over the past day.
